Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
Incidence and predictors of AF recurrence during long-term follow-up of patients after PF ablation for atrial fibrillation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Eberl Anna-Sophie, Manninger Martin, Rohrer Ursula, Stix Laura, Kurath-Koller Stefan, Gölly Katharina, Benedikt Martin, Bisping Egbert, Lercher Peter, Zirlik Andreas, Scherr Daniel
Аннотация
AIMS: Pulsed field ablation (PFA) is an established technology for pulmonary vein isolation (PVI) in patients with atrial fibrillation (AF). However, data on long-term outcome remain scarce. With this work, we aim to contribute valuable long-term data on catheter ablation with PFA.
METHODS AND RESULTS: We conducted a retrospective analysis of our single-centre data of 339 patients (63% paroxysmal AF, 37% persistent AF), as well as of 55 redo procedures in patients, who underwent first PVI with a pentaspline PFA catheter. During the median follow-up (FUP) of 752 (391-1486) days, 34% patients (n = 116) experienced arrhythmia recurrence after a blanking period of 90 days, with a median time to recurrence of 218 (90-1161) days. Multivariate analysis showed electrical cardioversion at the end [HR 1.97 (95% CI 1.17-3.33), P = 0.011] and AF at the beginning of the procedure [HR 1.73 (95% CI 1.04-2.88), P = 0.034] being independently associated with a higher risk of arrhythmia recurrence. Additional anterior flower applications were protective in the univariate (P = 0.025) analysis. Atrial tachycardia (AT) was present in 16, 37, 0, and 0% after the first, second, third, and fourth procedure, respectively. In 55 analysed redo procedures, 104/221 veins (47%) were reconnected (0/1/2/3/4 reconnected veins: 9%/31%/27.3%/27.3%/5.4%). Analysis of multiple procedure outcome estimates improved long-term arrhythmia-free survival, with an overall success rate of 86% after ≥2 procedures.
CONCLUSION: PV reconnections are frequent in patients presenting for repeat ablations, especially at the anterior PV aspect. A multiple procedure approach estimates arrhythmia-free survival in 86% of patients. Procedures with additional anterior lesions at the right pulmonary veins (RPVs) could be protective for recurrences.
METHODS AND RESULTS: We conducted a retrospective analysis of our single-centre data of 339 patients (63% paroxysmal AF, 37% persistent AF), as well as of 55 redo procedures in patients, who underwent first PVI with a pentaspline PFA catheter. During the median follow-up (FUP) of 752 (391-1486) days, 34% patients (n = 116) experienced arrhythmia recurrence after a blanking period of 90 days, with a median time to recurrence of 218 (90-1161) days. Multivariate analysis showed electrical cardioversion at the end [HR 1.97 (95% CI 1.17-3.33), P = 0.011] and AF at the beginning of the procedure [HR 1.73 (95% CI 1.04-2.88), P = 0.034] being independently associated with a higher risk of arrhythmia recurrence. Additional anterior flower applications were protective in the univariate (P = 0.025) analysis. Atrial tachycardia (AT) was present in 16, 37, 0, and 0% after the first, second, third, and fourth procedure, respectively. In 55 analysed redo procedures, 104/221 veins (47%) were reconnected (0/1/2/3/4 reconnected veins: 9%/31%/27.3%/27.3%/5.4%). Analysis of multiple procedure outcome estimates improved long-term arrhythmia-free survival, with an overall success rate of 86% after ≥2 procedures.
CONCLUSION: PV reconnections are frequent in patients presenting for repeat ablations, especially at the anterior PV aspect. A multiple procedure approach estimates arrhythmia-free survival in 86% of patients. Procedures with additional anterior lesions at the right pulmonary veins (RPVs) could be protective for recurrences.